Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study.

van der Straten A, Brown ER, Marrazzo JM, Chirenje MZ, Liu K, Gomez K, Marzinke MA, Piper JM, Hendrix CW; MTN-003 VOICE Protocol Team for Microbicide Trials Network.

J Int AIDS Soc. 2016 Feb 4;19(1):20642. doi: 10.7448/IAS.19.1.20642. eCollection 2016.

2.

Long-acting hormonal contraception.

Benagiano G, Gabelnick H, Brosens I.

Womens Health (Lond). 2015 Nov;11(6):749-57. doi: 10.2217/whe.15.68. Epub 2015 Dec 2. Review.

PMID:
26626534
3.

Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.

Abdool Karim SS, Abdool Karim Q, Kharsany AB, Baxter C, Grobler AC, Werner L, Kashuba A, Mansoor LE, Samsunder N, Mindel A, Gengiah TN; CAPRISA 004 Trial Group.

N Engl J Med. 2015 Aug 6;373(6):530-9. doi: 10.1056/NEJMoa1410649.

4.

Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, Palanee T, Nakabiito C, van der Straten A, Noguchi L, Hendrix CW, Dai JY, Ganesh S, Mkhize B, Taljaard M, Parikh UM, Piper J, Mâsse B, Grossman C, Rooney J, Schwartz JL, Watts H, Marzinke MA, Hillier SL, McGowan IM, Chirenje ZM; VOICE Study Team.

N Engl J Med. 2015 Feb 5;372(6):509-18. doi: 10.1056/NEJMoa1402269.

5.

First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy.

Anton PA, Saunders T, Elliott J, Khanukhova E, Dennis R, Adler A, Cortina G, Tanner K, Boscardin J, Cumberland WG, Zhou Y, Ventuneac A, Carballo-Diéguez A, Rabe L, McCormick T, Gabelnick H, Mauck C, McGowan I.

PLoS One. 2011;6(9):e23243. doi: 10.1371/journal.pone.0023243. Epub 2011 Sep 28.

6.

Contraceptive devices: intravaginal and intrauterine delivery systems.

Benagiano G, Gabelnick H, Farris M.

Expert Rev Med Devices. 2008 Sep;5(5):639-54. doi: 10.1586/17434440.5.5.639. Review.

PMID:
18803474
7.

Contraceptive devices: subcutaneous delivery systems.

Benagiano G, Gabelnick H, Farris M.

Expert Rev Med Devices. 2008 Sep;5(5):623-37. doi: 10.1586/17434440.5.5.623. Review.

PMID:
18803473
8.

Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission.

Van Damme L, Govinden R, Mirembe FM, Guédou F, Solomon S, Becker ML, Pradeep BS, Krishnan AK, Alary M, Pande B, Ramjee G, Deese J, Crucitti T, Taylor D; CS Study Group.

N Engl J Med. 2008 Jul 31;359(5):463-72. doi: 10.1056/NEJMoa0707957. Erratum in: N Engl J Med. 2008 Aug 21;359(8):877.

9.

10th Summit Meeting consensus: recommendations for regulatory approval for hormonal male contraception.

Aaltonen P, Amory JK, Anderson RA, Behre HM, Bialy G, Blithe D, Bone W, Bremner WJ, Colvard D, Cooper TG, Elliesen J, Gabelnick HL, Gu YQ, Handelsman DJ, Johansson EA, Kersemaekers W, Liu P, MacKay T, Matlin S, Mbizvo M, McLachlan RI, Meriggiola MC, Mletzko S, Mommers E, Muermans H, Nieschlag E, Odlind V, Page ST, Radlmaier A, Sitruk-Ware R, Swerdloff R, Wang C, Wu F, Zitzmann M.

J Androl. 2007 May-Jun;28(3):362-3. Epub 2006 Dec 27. No abstract available.

10.

A comparison of techniques to assess cervicovaginal irritation and evaluation of the variability between two observers.

Ballagh SA, Mauck CK, Henry D, Archer DF, Abercrombie T, Callahan MM, Gabelnick HL.

Contraception. 2004 Sep;70(3):241-9.

PMID:
15325894
11.

Current contraceptive research.

Schwartz JL, Gabelnick HL.

Perspect Sex Reprod Health. 2002 Nov-Dec;34(6):310-6. Review. No abstract available.

PMID:
12558094
12.

Pharmacokinetics of levonorgestrel 0.75 mg tablets.

Kook K, Gabelnick H, Duncan G.

Contraception. 2002 Jul;66(1):73-6.

PMID:
12169384
14.

The use of colposcopy in assessing vaginal irritation in research.

Mauck CK, Baker JM, Birnkrant DB, Rowe PJ, Gabelnick HL.

AIDS. 2000 Oct 20;14(15):2221-7. Review.

PMID:
11089609
15.

The promise of public/private sector collaboration in the development of vaginal microbicides.

Gabelnick HL, Harper MJ.

Int J Gynaecol Obstet. 1999 Dec;67 Suppl 2:S31-8.

PMID:
10661739
16.

The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy.

Mauck CK, Callahan MM, Baker J, Arbogast K, Veazey R, Stock R, Pan Z, Morrison CS, Chen-Mok M, Archer DF, Gabelnick HL.

Contraception. 1999 Jul;60(1):15-24.

PMID:
10549448
17.

Lea's Shield: a study of the safety and efficacy of a new vaginal barrier contraceptive used with and without spermicide.

Mauck C, Glover LH, Miller E, Allen S, Archer DF, Blumenthal P, Rosenzweig A, Dominik R, Sturgen K, Cooper J, Fingerhut F, Peacock L, Gabelnick HL.

Contraception. 1996 Jun;53(6):329-35.

PMID:
8773419
18.

Contraceptive efficacy and acceptability of the female condom.

Farr G, Gabelnick H, Sturgen K, Dorflinger L.

Am J Public Health. 1994 Dec;84(12):1960-4.

19.

Biodegradable systems for the sustained release of fertility-regulating agents.

Benagiano G, Gabelnick HL.

J Steroid Biochem. 1979 Jul;11(1B):449-55.

PMID:
114715
20.

Effects of cyclophosphamide and adriamycin on the healing of surgical wounds in mice.

Cohen SC, Gabelnick HL, Johnson RK, Goldin A.

Cancer. 1975 Oct;36(4):1277-81.

Supplemental Content

Loading ...
Support Center